ENGLISH DEUTSCH
WILEX is a biopharmaceutical company and develops drugs based on antibodies and small molecules with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. WILEX’ aim is to help oncologists administer targeted treatments to carefully diagnosed patients and to enhance patients' quality of life.
Latest News
12.04.2012: WILEX publishes financial report for the first quarter of 2012. WILEX AG today published its 3-month financial report for 2012 (1 December 2011 - 29 February 2012) and reported on the status of the Group’s projects. Peter Llewellyn-Davies, Chief Financial Officer of WILEX AG, commented: "We are pleased with our performance in the first quarter of 2012. ...... More.
Seite gelesen: 191 | Heute: 4